NCT00751062View on ClinicalTrials.gov

A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia

PHASE3CompletedINTERVENTIONAL
Enrollment

267

Participants

Timeline

Start Date

November 30, 1992

Primary Completion Date

December 31, 1993

Study Completion Date

December 31, 1993

Conditions
Open Angle GlaucomaOcular Hypertension
Interventions
DRUG

timolol

One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.

DRUG

PhXA41

One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle

Trial Locations (13)

Unknown

Pfizer Investigational Site, Hellerup

Pfizer Investigational Site, Vejle

Pfizer Investigational Site, Oulu

Pfizer Investigational Site, Bergen

Pfizer Investigational Site, Oslo

Pfizer Investigational Site, Trondheim

Pfizer Investigational Site, Gothenburg

Pfizer Investigational Site, Lund

Pfizer Investigational Site, Umeå

Pfizer Investigational Site, Uppsala

141 86

Pfizer Investigational Site, Huddinge

581 85

Pfizer Investigational Site, Linköping

205 02

Pfizer Investigational Site, Malmo

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00751062 - A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia | Biotech Hunter | Biotech Hunter